Docetaxel with prednisone or prednisolone for the treatment of ...

More documents

Recommendations

Info

Members Chair, Professor Tom Walley, Director, NHS HTA Programme, Department of Pharmacology & Therapeutics, University of Liverpool Members Programme Director, Professor Tom Walley, Director, NHS HTA Programme, Department of Pharmacology & Therapeutics, University of Liverpool Chair, Professor Jon Nicholl, Director, Medical Care Research Unit, University of Sheffield, School of Health and Related Research Deputy Chair, Professor Jenny Hewison, Professor of Health Care Psychology, Academic Unit of Psychiatry and Behavioural Sciences, University of Leeds School of Medicine Dr Jeffrey Aronson, Reader in Clinical Pharmacology, Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford Professor Deborah Ashby, Professor of Medical Statistics, Department of Environmental and Preventative Medicine, Queen Mary University of London Health Technology Assessment 2007; Vol. 11: No. 2 Health Technology Assessment Programme Director, Professor Tom Walley, Director, NHS HTA Programme, Department of Pharmacology & Therapeutics, University of Liverpool Prioritisation Strategy Group Professor Bruce Campbell, Consultant Vascular & General Surgeon, Royal Devon & Exeter Hospital Dr Edmund Jessop, Medical Advisor, National Specialist, Commissioning Advisory Group (NSCAG), Department of Health, London Deputy Director, Professor Jon Nicholl, Director, Medical Care Research Unit, University of Sheffield, School of Health and Related Research Professor Jon Nicholl, Director, Medical Care Research Unit, University of Sheffield, School of Health and Related Research Dr John Reynolds, Clinical Director, Acute General Medicine SDU, Radcliffe Hospital, Oxford HTA Commissioning Board Professor Ann Bowling, Professor of Health Services Research, Primary Care and Population Studies, University College London Professor John Cairns, Professor of Health Economics, Public Health Policy, London School of Hygiene and Tropical Medicine, London Professor Nicky Cullum, Director of Centre for Evidence Based Nursing, Department of Health Sciences, University of York Mr Jonathan Deeks, Senior Medical Statistician, Centre for Statistics in Medicine, University of Oxford Dr Andrew Farmer, Senior Lecturer in General Practice, Department of Primary Health Care, University of Oxford Professor Fiona J Gilbert, Professor of Radiology, Department of Radiology, University of Aberdeen Professor Adrian Grant, Director, Health Services Research Unit, University of Aberdeen Professor Freddie Hamdy, Professor of Urology, University of Sheffield Professor F D Richard Hobbs, Professor of Primary Care & General Practice, Department of Primary Care & General Practice, University of Birmingham Professor Alan House, Professor of Liaison Psychiatry, University of Leeds Professor Sallie Lamb, Professor of Rehabilitation, Centre for Primary Health Care, University of Warwick Professor Stuart Logan, Director of Health & Social Care Research, The Peninsula Medical School, Universities of Exeter & Plymouth Professor Miranda Mugford, Professor of Health Economics, University of East Anglia Current and past membership details of all HTA ‘committees’ are available from the HTA website (www.hta.ac.uk) © Queen’s Printer and Controller of HMSO 2007. All rights reserved. Dr Ron Zimmern, Director, Public Health Genetics Unit, Strangeways Research Laboratories, Cambridge Dr Linda Patterson, Consultant Physician, Department of Medicine, Burnley General Hospital Professor Ian Roberts, Professor of Epidemiology & Public Health, Intervention Research Unit, London School of Hygiene and Tropical Medicine Professor Mark Sculpher, Professor of Health Economics, Centre for Health Economics, Institute for Research in the Social Services, University of York Professor Kate Thomas, Professor of Complementary and Alternative Medicine, University of Leeds Professor Hywel Williams, Professor of Dermato-Epidemiology, University of Nottingham Ms Sue Ziebland, Research Director, DIPEx, Department of Primary Health Care, University of Oxford, Institute of Health Sciences 195
196 Health Technology Assessment Programme Members Chair, Dr Ron Zimmern, Director of the Public Health Genetics Unit, Strangeways Research Laboratories, Cambridge Ms Norma Armston, Freelance Consumer Advocate, Bolton Professor Max Bachmann, Professor of Health Care Interfaces, Department of Health Policy and Practice, University of East Anglia Professor Rudy Bilous Professor of Clinical Medicine & Consultant Physician, The Academic Centre, South Tees Hospitals NHS Trust Members Chair, Dr John Reynolds, Chair Division A, The John Radcliffe Hospital, Oxford Radcliffe Hospitals NHS Trust Ms Anne Baileff, Consultant Nurse in First Contact Care, Southampton City Primary Care Trust, University of Southampton Professor Imti Choonara, Professor in Child Health, Academic Division of Child Health, University of Nottingham Diagnostic Technologies & Screening Panel Dr Paul Cockcroft, Consultant Medical Microbiologist and Clinical Director of Pathology, Department of Clinical Microbiology, St Mary's Hospital, Portsmouth Professor Adrian K Dixon, Professor of Radiology, University Department of Radiology, University of Cambridge Clinical School Dr David Elliman, Consultant Paediatrician/ Hon. Senior Lecturer, Population Health Unit, Great Ormond St. Hospital, London Professor Glyn Elwyn, Primary Medical Care Research Group, Swansea Clinical School, University of Wales Swansea Professor Paul Glasziou, Director, Centre for Evidence-Based Practice, University of Oxford Dr Jennifer J Kurinczuk, Consultant Clinical Epidemiologist, National Perinatal Epidemiology Unit, Oxford Dr Susanne M Ludgate, Medical Director, Medicines & Healthcare Products Regulatory Agency, London Mr Stephen Pilling, Director, Centre for Outcomes, Research & Effectiveness, Joint Director, National Collaborating Centre for Mental Health, University College London Dr Phil Shackley, Senior Lecturer in Health Economics, School of Population and Health Sciences, University of Newcastle upon Tyne Pharmaceuticals Panel Dr Robin Ferner, Consultant Physician and Director, West Midlands Centre for Adverse Drug Reactions, City Hospital NHS Trust, Birmingham Professor John Geddes, Professor of Epidemiological Psychiatry, University of Oxford Mrs Barbara Greggains, Non-Executive Director, Greggains Management Ltd Dr Bill Gutteridge, Medical Adviser, National Specialist Commissioning Advisory Group (NSCAG), London Mrs Sharon Hart, Consultant Pharmaceutical Adviser, Reading Dr Jon Karnon, Senior Research Fellow, Health Economics and Decision Science, University of Sheffield Dr Yoon Loke, Senior Lecturer in Clinical Pharmacology, University of East Anglia Ms Barbara Meredith, Lay Member, Epsom Dr Andrew Prentice, Senior Lecturer and Consultant Obstetrician & Gynaecologist, Department of Obstetrics & Gynaecology, University of Cambridge Dr Frances Rotblat, CPMP Delegate, Medicines & Healthcare Products Regulatory Agency, London Current and past membership details of all HTA ‘committees’ are available from the HTA website (www.hta.ac.uk) Dr Margaret Somerville, Director of Public Health Learning, Peninsula Medical School, University of Plymouth Dr Graham Taylor, Scientific Director & Senior Lecturer, Regional DNA Laboratory, The Leeds Teaching Hospitals Professor Lindsay Wilson Turnbull, Scientific Director, Centre for MR Investigations & YCR Professor of Radiology, University of Hull Professor Martin J Whittle, Clinical Co-director, National Co-ordinating Centre for Women’s and Childhealth Dr Dennis Wright, Consultant Biochemist & Clinical Director, Pathology & The Kennedy Galton Centre, Northwick Park & St Mark’s Hospitals, Harrow Dr Martin Shelly, General Practitioner, Leeds Mrs Katrina Simister, Assistant Director New Medicines, National Prescribing Centre, Liverpool Dr Richard Tiner, Medical Director, Medical Department, Association of the British Pharmaceutical Industry, London
Page 1 and 2:
A systematic review and economic mo
Page 3 and 4:
A systematic review and economic mo
Page 5 and 6:
Objectives: A systematic review was
Page 7 and 8:
Glossary and list of abbreviations
Page 9 and 10:
Glossary Absolute risk reduction Th
Page 11 and 12:
Glossary continued Expected value o
Page 13 and 14:
Glossary continued Progression-free
Page 15:
List of abbreviations ASCO American
Page 18 and 19:
xvi Executive summary of study desi
Page 20 and 21:
xviii Executive summary prednisone/
Page 23 and 24:
Description of underlying health pr
Page 25 and 26:
● Patients with severe fluid rete
Page 27 and 28:
Search strategy As stated in Chapte
Page 29 and 30:
consensus and, if necessary, a thir
Page 31 and 32:
Quantity of research available A to
Page 33 and 34:
TABLE 1 Summary of included RCTs St
Page 35 and 36:
TABLE 2 Treatment comparisons relat
Page 37 and 38:
tumour response was reported for on
Page 39 and 40:
TABLE 4 Summary results table for d
Page 41 and 42:
decrease in PSA level (51 and 39% c
Page 43 and 44:
Survival (%) 100 80 60 40 20 0 0 co
Page 45 and 46:
TABLE 8 Summary results table for d
Page 47 and 48:
TABLE 9 Grade 3 or 4 adverse events
Page 49 and 50:
Also used was the core questionnair
Page 51 and 52:
these, 69 patients had measurable t
Page 53 and 54:
Effectiveness of mitoxantrone plus
Page 55 and 56:
over to receive additional mitoxant
Page 57 and 58:
Progression-free survival It is not
Page 59 and 60:
compared with corticosteroids. The
Page 61 and 62:
statistically significant improveme
Page 63 and 64:
Summary of studies included in the
Page 65 and 66:
TABLE 19 Percentage of costs by res
Page 67 and 68:
TABLE 21 Summary of submission by S
Page 69 and 70:
TABLE 24 Other in-trial costs a bod
Page 71 and 72:
TABLE 27 Cost-effectiveness results
Page 73 and 74:
Introduction The review of cost-eff
Page 75 and 76:
TABLE 28 Regression coefficients fr
Page 77 and 78:
cancer QoL estimation. Studies whic
Page 79 and 80:
Localised Metastatic mHRPC Bennet (
Page 81 and 82:
TABLE 34 Unit costs of drugs from t
Page 83 and 84:
were assigned to the total follow-u
Page 85 and 86:
Probability cost-effective given da
Page 87 and 88:
Probability cost-effective given da
Page 89 and 90:
TABLE 43 Utility values including/e
Page 91 and 92:
was set to be 1.5 years based on th
Page 93:
Population value of implementation/
Page 96 and 97:
76 Discussion (CCI-NOV22) and least
Page 98 and 99:
78 Discussion subsequent chemothera
Page 101:
Rodolphe Perard received funding fr
Page 104 and 105:
84 References Compendium; 2004. URL
Page 106 and 107:
86 References (D) in patients (pts)
Page 108 and 109:
88 References 100. Aventis Pharma.
Page 110 and 111:
90 References low-dose prednisone i
Page 112 and 113:
92 References 180. Kozloff M, Robin
Page 114 and 115:
94 References locally advanced pros
Page 116 and 117:
96 References 251. Scholz MC, Guess
Page 119 and 120:
Clinical effectiveness Searching fo
Page 121 and 122:
1. Prostatic Intraepithelial Neopla
Page 123 and 124:
19. donataxel 20. doxetal 21. doxmi
Page 125 and 126:
6. Mitozantrone.ti,ab. 7. Mitoxantr
Page 127 and 128:
Texot or Trazoteva or Trixotene or
Page 129 and 130:
1. (docetaxel OR asodecel OR doxeta
Page 131 and 132:
10. (index of wellbeing or quality
Page 133 and 134:
Appendix 2 Excluded studies Study d
Page 135 and 136:
Study details Reason for exclusion
Page 137 and 138:
Meeting: 2004 ASCO Annual Meeting C
Page 139 and 140:
Studies of clinical effectiveness w
Page 141 and 142:
Using the method outlined by Parmar
Page 143 and 144:
Appendix 6 Data extraction tables
Page 145 and 146:
Study details and Participant detai
Page 147 and 148:
Study details and Participant detai
Page 149 and 150: Study details and Participant detai
Page 175: Study details and Participant detai
Page 178 and 179: 158 Appendix 7 Ernst et al. 33 Qual
Page 181 and 182: Appendix 9 © Queen’s Printer and
Page 183 and 184: Sanofi-Aventis 61 Bloomfield et al.
Page 185: Sanofi-Aventis 61 Bloomfield et al.
Page 188 and 189: 168 Appendix 10 TABLE 51 Mean (SD)
Page 190 and 191: 170 Appendix 10 TABLE 54 Distributi
Page 192 and 193: 172 Appendix 10 TABLE 57 Mean stand
Page 194 and 195: 174 Appendix 11 TABLE 63 Drug and a
Page 196 and 197: 176 Appendix 12 Scenario: moderate
Page 198 and 199: 178 Appendix 13 ● You occasionall
Page 204 and 205: Members Chair, Professor Bruce Camp
Page 207: Feedback The HTA Programme and the
show all

Docetaxel with prednisone or prednisolone for the treatment of ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?